Back to Search
Start Over
THE EFFICACY AND SAFETY OF ALIROCUMAB IN PEDIATRIC PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: ODYSSEY KIDS
- Source :
- Journal of the American College of Cardiology. 75:1860
- Publication Year :
- 2020
- Publisher :
- Elsevier BV, 2020.
-
Abstract
- A Phase 2 dose-finding study ([NCT02890992][1]) evaluated the efficacy, safety, and dose selection of the PCSK9 inhibitor alirocumab in pediatric patients with heterozygous familial hypercholesterolemia (HeFH). Patients (N=42) aged 8–17 years, with body weight ≥25 kg and with HeFH and LDL-C ≥
Details
- ISSN :
- 07351097 and 02890992
- Volume :
- 75
- Database :
- OpenAIRE
- Journal :
- Journal of the American College of Cardiology
- Accession number :
- edsair.doi...........cfdf18309ae955eb38054bea99bebdbb
- Full Text :
- https://doi.org/10.1016/s0735-1097(20)32487-6